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Background 
Mycobacterium vaccae has been assessed as a potential 
immunotherapeutic treatment in tuberculosis (TB) (l-6) 
with apparent success. However, these trials were 
performed in centres where TB is severe, drug resistance is 
widespread, conventional therapy is not optimal and there 
is a relatively high mortality rate (7). As a prelude to further 
studies in a country where there is good response to 
standard chemotherapy and low mortality, a small double- 
blind, placebo-controlled study was undertaken to identify 
optimum indices of disease activity for use as outcome 
measures of efficacy and to assess the safety of M. vaccae. 
Methods 
Eleven patients (ten male, one female) with fully sensitive 
and bacteriologically proven active pulmonary TB partici- 
pated (mean age, 40 years; range, 21-58 years). Six patients 
were randomized into the placebo group and five into the 
active group. All gave informed consent and the study 
was approved by the St. Mary’s Local Research Ethics 
Committee. 
This was a randomized double-blind, placebo-controlled 
study. Following diagnosis all subjects were started on 
conventional anti-tuberculous chemotherapy (rifampicin, 
isoniazid and pyrazinamide for 2 months followed by 
rifampicin and isoniazid for a further 4 months). From 1 
to 2 weeks later, a single intradermal injection of 0.1 ml of 
M. vaccae or saline was given. Subjects were followed up by 
a ‘blinded’ physician and progress monitored by weight, 
chest radiographs, erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) for a total of 4 months. In 
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addition soluble interleukin-2 receptor (sIL-2R), the 
percentage of IgG that is of the agalactosyl glyco- 
form [Gal(O) I(%)] and concentrations of antibody to 
lipoarabinomannan (anti-LAM) were analysed. 
Chest radiographs were reported on and graded accord- 
ing to a modification of the WHO guidelines (8) by a 
radiologist blinded to the treatment code. This score ranged 
from trivial changes (score 1) to extensive disease (score 8). 
sIL-2R was measured with a kit in accordance with the 
manufacturer’s instructions (Medgenix diagnostics SA; 
code 40 027 00). Anti-LAM and Gal(O) (%) measure- 
ments were performed as described previously with minor 
modifications (9). 
Results 
All patients who received active treatment tolerated the 
injection of M. vaccae well. Two subjects had a small, 
localized pustular reaction at the site of injection which 
resolved spontaneously over 72 h. There were no systemic 
reactions and no long-term scarring. One subject in the 
active group suffered from a myocardial infarction after 
12 weeks but this was not felt to be related to the 
immunotherapy. 
With the exception of two subjects from the placebo 
group, all patients had an increase in their weight. The 
median gain in the active group was 4.2 kg (range 1.8- 
10 kg) and placebo 6.15 kg (range - 2.5 kg to+8.2 kg). All 
subjects demonstrated a decrease in ESR with a median fall 
in the active group of 24 mm h ~ ’ (range l&64 mm h - ‘) 
and in the placebo group 19mmh-’ (range 
1-57 mm h - I). There was an improvement in CRP concen- 
trations in all subjects (Fig. 1) with a median reduction in 
the active group of 30 mg 1 - ’ (range O-99 mg) 1~ ’ and in 
the placebo group of 31.5 mg l- ’ (range O-106 mg 1~ ‘). 
Individuals with the highest initial CRP concentrations 
tended to have abnormal concentrations at 16 weeks but 
improvements were more clearly seen in these patients. The 
results for CRP exhibited the least fluctuation when results 
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FIG. 1. Changes in CRP (mg 1 - ‘) over 16 weeks in 
individual patients: open symbols, placebo (n=6); full 
symbols, M. vaccae (n=5). 
from all parameters were compared. With the exception of 
one subject, there was an improvement in sIL-2R concen- 
trations in all patients with a median reduction in the active 
group of 410 units ml-’ (range 72-1179 units ml- ‘) and 
the placebo group 906 units ml - ’ (range+299 to - 1327 
units ml - i). There was a median improvement in chest 
radiograph scores in the active group of 1.0 (range o-4) 
and in the placebo group of 1.5 (range O-6). There was 
no consistent change in the level of Gal(O) (%) and 
anti-LAM. 
As the majority of patients were unable to produce 
sputum after treatment we were unable to assess the rate of 
change in sputum positivity. Furthermore, two subjects had 
only been diagnosed after either a bronchoalveolar lavage 
or after sputum culture at 5 weeks. 
There were no significant differences in the changes of the 
parameters measured, between active and placebo groups. 
Significant correlations were noted between the chest radio- 
graph score and ESR (r=0.46, P=O.O3), CRP (r=0.57, 
P=O.OOS) and sIL-2R (r=0.61), P=O.O03) but not between 
the change in weight and these parameters. 
Discussion 9. 
In this small study, M. vaccae appeared to be well tolerated 
and did not produce any serious adverse effects. 
We also observed that surrogate markers of disease 
activity are unsatisfactory. Although there was a trend to 
improvement in the parameters measured there was a high 
noise-to-signal ratio and we were unable to demonstrate 
any statistically significant difference between treatment 
groups. There appeared to be a good correlation between 
the inflammatory markers and chest radiograph scores 
although this could not be demonstrated for the changes in 
weight. 
This study illustrates the problems of studies in the 
developed world in establishing outcome measures to assess 
the efficacy of novel treatments of TB in the context of 
effective chemotherapy. 
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